SCHEMBL25280464

SCHEMBL25280464

CCOc1ccc(C(=O)N2CCN(CCCCc3ccccc3)CC2)cc1OCC

nearest known ligand 0.86

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
SIGMAR1 Q99720 2/20 0.65
ALOX15 P16050 1/20 0.64
HSD17B10 Q99714 2/20 0.61
NPSR1 Q6W5P4 2/20 0.60
HPGD P15428 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
PKM P14618 1/20 0.54
MAPK1 P28482 1/20 0.54
KCNH2 Q12809 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
HTR2A P28223 1/20 0.53
HTR7 P34969 1/20 0.53
OPRM1 P35372 1/20 0.53
DRD2 P14416 1/20 0.52
GLA P06280 1/20 0.52
TSHR P16473 1/20 0.50
USP2 O75604 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31178342 1.00 MEN1 (0.69) MEN1KMT2ASIGMAR1ALOX15HSD17B10
SCHEMBL25732854 0.97 MEN1 (0.74) MEN1KMT2ASIGMAR1ALOX15HSD17B10
SCHEMBL25732877 0.92 ALOX15 (0.68) MEN1KMT2ASIGMAR1ALOX15HSD17B10
SCHEMBL31178349 0.88 ALOX15 (0.63) MEN1KMT2ASIGMAR1ALOX15HSD17B10
SCHEMBL25239701 0.88 ALOX15 (0.63) MEN1KMT2ASIGMAR1ALOX15HSD17B10
SCHEMBL31178332 0.87 KMT2A (0.90) MEN1KMT2ASIGMAR1DRD2TSHR
SCHEMBL25237358 0.87 KMT2A (0.90) MEN1KMT2ASIGMAR1DRD2TSHR
SCHEMBL25241368 0.86 SIGMAR1 (0.73) MEN1KMT2ASIGMAR1HSD17B10HPGD
SCHEMBL31326931 0.85 MAPK1 (0.72) MEN1KMT2AALOX15HSD17B10NPSR1
SCHEMBL25732875 0.85 MAPK1 (0.72) MEN1KMT2AALOX15HSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same SYMRISE AG (DE) 2025-02-27 US disclosed
EP-4452941-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-10-30 EP disclosed
WO-2023117119-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-06-29 WO disclosed
WO-2023117119-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same TAS2R5, TAS2R7, TAS2R8 MEN1 714/4885KMT2A 2748/4885SIGMAR1 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.